Ignite Creation Date:
2024-05-06 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04731909
Status:
UNKNOWN
Last Update Posted:
2021-02-10
First Post:
2021-01-27
Brief Title:
Toripalimab Combined With Anlotinib Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
Sponsor:
Third Military Medical University
Organization:
Third Military Medical University
Study Overview
Official Title:
Clinical Study of Toripalimab Combined With Anlotinib Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluates the effectiveness and safety of Toripalimab combined with Anlotinib and chemotherapy for the first-line treatment of ES-SCLC and maintenance therapy are Toripalimab combined with Anlotinib
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None